Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may "activate" the liver, potentially restoring nor
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may "activate" the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.
대표청구항▼
What is claimed is: 1. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising: orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an insulin polypeptide-oligomer conjugate comprising the structure o
What is claimed is: 1. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising: orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an insulin polypeptide-oligomer conjugate comprising the structure of Formula III: description="In-line Formulae" end="lead"Insulin polypeptide-X(CH2)m(OC2H4)n OR (III)description="In-line Formulae" end="tail" wherein: X is a moiety which forms an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient within one hour prior to ingestion of a meal or contemporaneously with ingestion of a meal by the human patient in order to treat diabetes mellitus in the human patient, wherein the effective amount of the conjugate of Formula III is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. 2. The method of claim 1, wherein the oral administration of the effective amount of the conjugate of Formula III provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 30 minutes of administration. 3. The method of claim 1, wherein the oral administration of the effective amount of the conjugate of Formula III provides a maximum insulin drug concentration in peripheral blood within about 60 minutes after administration. 4. The method of claim 1, wherein the oral administration of the effective amount of the conjugate of Formula III stabilizes peripheral glucose concentration to within about +/-50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration. 5. The method of claim 1, wherein the conjugate of Formula III clears the bloodstream of the human patient within about 4 hours following administration. 6. The method of claim 1, wherein the administration of the effective amount of the conjugate of Formula III reduces hepatic glucose production in the human patient by at least about 25 percent when compared to hepatic glucose production in the human patient without administration. 7. The method of claim 6, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration. 8. The method of claim 1, wherein the conjugate of Formula III is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the human patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the human patient. 9. The method of claim 1, wherein the conjugate of Formula III is orally administered less than about one hour prior to ingestion of a meal by the human patient. 10. The method of claim 1, wherein the conjugate of Formula III is orally administered substantially contemporaneously with the ingestion of a meal by the human patient. 11. The method of claim 1, wherein the conjugate of Formula III is orally administered less than about one hour after ingestion of a meal by the human patient. 12. The method of claim 1, wherein the insulin polypeptide is insulin. 13. The method of claim 12, wherein the oligomer is coupled to the lysine at the B29 position of the insulin. 14. A method of claim 1, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; Ala B28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 Pro B29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human. 15. The method of claim 1, wherein the conjugate of Formula III is present as a substantially monodispersed mixture. 16. The method of claim 1, wherein the conjugate of Formula III is present as a monodispersed mixture. 17. The method of claim 1, wherein the conjugate of Formula III is amphiphilically balanced. 18. The method of claim 1, wherein the effective amount of the conjugate of Formula III is present in a pharmaceutical composition. 19. The method of claim 1, wherein m is between 3 and 16. 20. The method of claim 1, wherein m is between 4 and 14. 21. The method of claim 1, wherein m is between 5 and 10. 22. The method of claim 1, wherein n is between 3 and 18. 23. The method of claim 1, wherein n is between 4 and 14. 24. The method of claim 1, wherein n is between 5 and 10. 25. The method of claim 1, wherein R is lower alkyl. 26. The method of claim 1, wherein R is C1 to C3 alkyl. 27. The method of claim 1, wherein R is methyl. 28. The method of claim 1, wherein the insulin polypeptide-oligomer conjugate comprises the structure of Formula IV: 29. The method of claim 28, wherein the oral administration of the effective amount of the conjugate of Formula IV provides an insulin drug concentration in portal vein blood between about 10 and 1, 000 U/ml within about 30 minutes of administration. 30. The method of claim 28, wherein the effective amount of the conjugate of Formula IV is between about 0.05 and about 10 mg per kilogram body weight. 31. The method of claim 28, wherein the oral administration of the effective amount of the conjugate of Formula IV provides a maximum insulin drug concentration in peripheral blood within about 60 minutes after administration. 32. The method of claim 28, wherein the oral administration of the effective amount of the conjugate of Formula IV stabilizes peripheral glucose concentration to within about +/-50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration. 33. The method of claim 28, wherein the conjugate of Formula IV clears the bloodstream of the human patient within about 4 hours following administration. 34. The method of claim 28, wherein the administration of the effective amount of the conjugate of Formula IV reduces hepatic glucose production in the human patient by at least about 25 percent when compared to hepatic glucose production in the human patient without administration. 35. The method of claim 34, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration. 36. The method of claim 28, wherein the conjugate of Formula IV is orally administered such that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the human patient is hepatically absorbed within about 120 minutes after ingestion of the meal by the human patient. 37. The method of claim 28, wherein the conjugate of Formula IV is orally administered less than about one hour prior to ingestion of a meal by the human patient. 38. The method of claim 28, wherein the conjugate of Formula IV is orally administered substantially contemporaneously with the ingestion of a meal by the human patient. 39. The method of claim 28, wherein the conjugate of Formula IV is orally administered less than about one hour after ingestion of a meal by the human patient. 40. The method of claim 28, wherein the insulin polypeptide is insulin. 41. The method of claim 40, wherein the oligomer is coupled to the lysine at the B29 position of the insulin. 42. A method of claim 28, wherein the insulin polypeptide is an insulin analog selected from the group consisting of GlyA21 insulin, human; GlyA21 GlnB3 insulin, human; AlaA21 insulin, human; AlaA21 GlnB3 insulin, human; GlnB3 insulin, human; GlnB30 insulin, human; GlyA21 GluB30 insulin, human; GlyA21 GlnB3 GluB30 insulin, human; GlnB3 GluB30 insulin, human; AspB28 insulin, human; LysB28 insulin, human; LeuB28 insulin, human; ValB28 insulin, human; Ala B28 insulin, human; AspB28 ProB29 insulin, human; LysB28 ProB29 insulin, human; LeuB28 Pro B29 insulin, human; ValB28 ProB29 insulin, human; and AlaB28 ProB29 insulin, human. 43. The method of claim 28, wherein the conjugate of Formula IV is present as a substantially monodispersed mixture. 44. The method of claim 28, wherein the conjugate of Formula IV is present as a monodispersed mixture. 45. The method of claim 28, wherein the conjugate of Formula IV is amphiphilically balanced. 46. The method of claim 28, wherein the effective amount of the conjugate of Formula IV is present in a pharmaceutical composition. 47. The method of claim 28, wherein m is between 3 and 16. 48. The method of claim 28, wherein m is between 4 and 14. 49. The method of claim 28, wherein m is between 5 and 10. 50. The method of claim 28, wherein n is between 3 and 18. 51. The method of claim 28, wherein n is between 4 and 14. 52. The method of claim 28, wherein n is between 5 and 10. 53. The method of claim 28, wherein R is lower alkyl. 54. The method of claim 28, wherein R is C1 to C 3 alkyl. 55. The method of claim 28, wherein R is methyl. 56. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising: orally administering to the human patient an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III: description="In-line Formulae" end="lead"Insulin polypeptide-X(CH2)m(OC2H4)n OR (III)description="In-line Formulae" end="tail" wherein: X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to treat diabetes mellitus in the human patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. 57. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising: orally administering to the human patient an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III: description="In-line Formulae" end="lead"Insulin polypeptide-X(CH2)m(OC2H4)n OR (III)description="In-line Formulae" end="tail" wherein: X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/-50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration. 58. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising: orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an insulin polypeptide-oligomer conjugate comprising the structure of Formula III: description="In-line Formulae" end="lead"Insulin polypeptide-X(CH2)m(OC2H4)n OR (III)description="In-line Formulae" end="tail" wherein: X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the human patient without administration. 59. The method of claim 58, wherein the reduction in hepatic glucose production occurs within about 90 minutes after administration. 60. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising: orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III: description="In-line Formulae" end="lead"Insulin polypeptide-X(CH2)m(OC2H4)n OR (III)description="In-line Formulae" end="tail" wherein: X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the human patient. 61. The method of claim 57 wherein the insulin polypeptide-oligomer conjugate comprises the structure of Formula IV: wherein: m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; and is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of oral administration to the human patient.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (164)
Greenwald Richard B. ; Gilbert Carl W., .alpha.-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same.
Belagaje Rama M. (Indianapolis IN) DiMarchi Richard D. (Carmel IN) Heath ; Jr. William F. (Indianapolis IN) Long Harlan B. (Carmel IN), A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production.
Kitao Kazuhiko (Kyoto JPX) Nishimura Ken-ichi (Kyoto JPX), Adjuvant for promoting absorption of pharmacologically active substances through the rectum.
Speaker Tully J. (Philadelphia PA) Speaker Tycho J. (Philadelphia PA) Collett John H. (Sale GB2), Adjuvant-enhanced sustained release composition and method for making.
Ekwuribe Nnochiri ; Ramaswamy Muthukumar ; Rajagopalan Jayanthi Sethuraman, Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same.
Vanlerberghe Guy (Commune de Villevaude FRX) Handjani Rose-Marie (Paris FRX), Aqueous dispersions of lipid spheres and compositions containing the same.
Veronese Francesco (Padua ITX) Sartore Luciana (Padua ITX) Orsolini Piero (Martigny CHX) Deghenghi Romano (S.-Cergue CHX), Biologically active drug polymer derivatives and method for preparing same.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Biologically inert, biocompatible-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates containing an ether linkage.
Mill Patrick James (Beaconfield EN) Cresswell Michael Alan (High Wycombe EN) Feinberg Joseph George (London EN), Conjugates of acid polysaccharides and complex organic substances.
Saifer Mark (Berkeley CA) Somack Ralph (Oakland CA) Williams L. David (Fremont CA), Conjugates of superoxide dismutage coupled to high molecular weight polyalkylene glycols.
Ekwuribe Nnochiri N. (Southfield MI), Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and m.
Ekwuribe Nnochiri N. (Southfield MI), Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and m.
Huper Fritz (Wuppertal DT) Rauenbusch Erich (Wuppertal DT) Schmidt-Kastner Gunter (Wuppertal DT) Bomer Bruno (Leverkusen DT) Bartl Herbert (Odenthal-Hahnenberg DT), Crosslinked copolymers of ab
상세보기
Greenwald Richard B. (Somerset NJ) Martinez Anthony J. (Hamilton Square NJ), Cyclic imide thione activated polyalkylene oxides.
Shorr Robert G. L. (Edison NJ) Cho Myung-Ok P. (Highland Park NJ) Nho Kwang (Somerset NJ), Fractionation of polyalkylene oxide-conjugated hemoglobin solutions.
Buckley Douglas I. (215 Brookward Rd. Woodside CA 94062) Habener Joel F. (217 Plymouth Rd. Newton Highlands MA 02161) Mallory Joanne B. (199 Acalanes ; Apt. 3 Sunnyvale CA 94086) Mojsov Svetlana (504, GLP-1 analogs useful for diabetes treatment.
Kahne Daniel Evan (Princeton NJ) Kahne Suzanne Walker (Princeton NJ), Glycosylated steroid derivatives for transport across biological membranes and process for making and using same.
Newhouse Stanley (206 Juniper Cir. North Lawrence NY 11559) Lerner Robert (315 E. 65th St. New York NY 10021) Martin Roy (3312 182nd Pl. ; NE. Redmond WA 98452), Insulin delivery method and apparatus.
DePrince Randolph B. (Terre Haute IN) Viswanathan Ravi (Terre Haute IN), Layered, compression molded device for the sustained release of a beneficial agent.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Phillips Christopher P. (Brandamore PA) Snow Robert A. (West Chester PA), Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin.
Sutton Peter M. (Manderley GB2) Atkinson Anthony (Twingley GB2) Lloyd Graham (East Gomeldon GB2), Method and composition for the treatment and prevention of viral infections.
Brownlee Michael (Watertown MA) Cerami Anthony (Flanders NJ), Method and system for the controlled release of biologically active substances to a body fluid.
Brownlee Michael (Watertown MA) Cerami Anthony (Flanders NJ), Method and system for the controlled release of biologically active substances to a body fluid.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Method of preparing collagen-polymer conjugates.
Weiner Howard L. ; Eisenberth George ; Hafler David Allen ; Zhang Zhengi, Method of treating or preventing type 1 diabetes by oral administration of insulin.
Phillips William T. (San Antonio TX) Schwartz Joyce G. (San Antonio TX) Green Gary M. (San Antonio TX), Methods of normalizing metabolic parameters in diabetics.
Harris J. Milton ; Veronese Francesco Maria,ITX ; Caliceti Paolo,ITX ; Schiavon Oddone,ITX, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces.
Davis Frank F. (19 Farmingdale Rd. East Brunswick NJ 08816) Van Es Theodorus (313 Overbrook Rd. Piscataway NJ 08854) Palczuk Nicholas C. (45 W. Franklin St. Bound Brook NJ 08805), Non-immunogenic polypeptides.
Parker Brian A.,IEX ; Holejko Longin V. ; Cullen Barry A. ; Davis Jonathan D., Pesticidal compositions comprising solutions of polyurea and/or polyurethane.
Henry R. Jones GB; Fariba Shojaee-Moradi GB; Peter Henri Sonksen GB; Dietrich Brandenburg DE; Achim Schuttler DE; Heike Eckey DE; Erik Sundermann DE, Pharmaceutical active conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates.
Nitecki Danute E. (Berkeley CA) Katre Nandini (El Cerrito CA) Goodson Robert J. (Albany CA) Aldwin Lois (San Mateo CA), Preparation of a polymer/interleukin-2 conjugate.
Baker Jeffrey Clayton (Indianapolis IN) Moser Brian A. (Indianapolis IN) Shrader Warren E. (Indianapolis IN), Preparation of an acylated protein powder.
Baker Jeffrey C. (Indianapolis IN) Carter Nancy D. (Indianapolis IN) Frank Bruce H. (Indianapolis IN), Preparation of stable zinc insulin analog crystals.
Appelgren Curt H. (Kungsbacka SEX) Eskilsson Eva C. (Mlnlycke SEX) Uvdal Jonas P. (Gothenburg SEX), Process for preparing rapidly disintegrating granulates.
Maitra Amarnath,INX ; Ghosh Prashant Kumar,INX ; De Tapas K.,INX ; Sahoo Sanjeeb Kumar,INX, Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles.
Frank Bruce H. (Indianapolis IN) Prouty Walker E. (Indianapolis IN) Heiney Richard E. (Greenwood IN) Walden Mark R. (Indianapolis IN), Process for transforming a human insulin precursor to human insulin.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Processes for preparing compositions for inhalation.
Eckenhoff James B. (Los Altos CA) Cortese Richard (Los Gatos CA) Landrau Felix A. (Milpitas CA), Rate controlled dispenser for administering beneficial agent.
Baker Jeffrey C. (Indianapolis IN) Hanquier Jose M. (Martinsville IN) Shrader Warren E. (Indianapolis IN), Reducing gelation of a fatty acid-acylated protein.
Baker Jeffrey C. (Indianapolis IN) Chen Victor J. (Indianapolis IN) Hanquier Jose M. (Martinsville IN) Kriauciunas Aidas (Indianapolis IN) Moser Brian A. (Indianapolis IN) Shuman Robert T. (Greenwood, Selective acylation of epsilon-amino groups.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Backstrom Kjell Goran Erik (Lund SEX) Dahlback Carl Magnus Olof (Lund SEX) Edman Peter (Bjarred SEX) Johansson Ann Charlotte Birgit (Lund SEX), Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Longenecker John P. (Mountain View CA) Ennis Richard (Fremont CA) Baldwin Patricia A. (Hayward CA) Lee William A. (Los Altos CA), Transmembrane formulations for drug administration.
Ekwuribe,Nnochiri N.; Price,Christopher H.; Ansari,Aslam M.; Radhakrishnan,Balasingam; Odenbaugh,Amy L., Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.